much lower at community doses Vomiting up to 36% at high doses Diarrhea 23-26% Constipation 17-19% Fatigue 11-13% Pancreatitis risk trials flagged severe abdominal pain for discontinuation and evaluation Gallbladder issues rapid weight loss increases gallstone risk Thyroid C-cell tumors same boxed warning as semaglutide (animal studies) GI side effects were more intense than semaglutide in trial data due to the dual mechanism
Be gentle -Avoid exfoliants, scrubs, or any products with harsh actives
Retatrutide and cagrilintide remain investigational worldwide and carry no approval for human use
Therapy with a GLP-1 RA or sodium-glucose cotransporter 2 inhibitor (SGLT2 inhibitor) that has proven CV benefit is recommended for initial therapy, with or without metformin based on glycemic needs, in patients with indicators of high-risk or established CV disease
Thats why I went to Washington, D.C., in July and testified before an FDA advisory committee in support of legal, physician-supervised access to peptides
Our team has seen this pattern across multiple peptide classes